Login to Your Account



Kael-Gemvax Forging Ahead Despite Cancer Vaccine Failure

By Nuala Moran
Staff Writer

Wednesday, June 19, 2013
LONDON – South Korean biotech Kael-Gemvax is planning further investment and new clinical trials of GV1001, despite the cancer vaccine failing to meet the primary endpoint in a 1,062-patient UK Phase III trial that reported earlier this month.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription